Moreover, genetic- or biologics-based co-blockade of TIGIT and CD96 has been shown to improve tumor control while co-blockade of TIGIT and PVRIG has also been shown to promote NK cell function (152, 157). This evidence concerns the gene PVRIG and neoplasm.